Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy

Cell & Bioscience

Huilan Yang¹  Haihua Ye²  Xiuyun Xuan²  Yan Liang²  Changzheng Huang²  Ting Wu²  Juanmei Cao²  Fangqi Chen²  Lin Zhang³  Chunxia Tian⁴ 

[1] Department of Dermatology, General Hospital of Southern Theatre Command;Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology;Department of Gerontology, Jinan City People’s Hospital;Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology;

关键词: Connective tissue diseases;    Interleukin-22;    Cytokine;    IL-22R;    Signalling pathway;   

DOI  :  10.1186/s13578-020-00504-1

来源: DOAJ

【 摘 要 】

Abstract Interleukin-22 (IL-22), a member of the IL-10 family of cytokines, is produced by a number of immune cells involved in the immune microenvironment of the body. IL-22 plays its pivotal roles by binding to the IL-22 receptor complex (IL-22R) and subsequently activating the IL-22R downstream signalling pathway. It has recently been reported that IL-22 also contributes to the pathogenesis of many connective tissue diseases (CTDs). In this review, we will discuss the role of IL-22 in several CTDs, such as system lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis and dermatomyositis, suggesting that IL-22 may be a potential therapeutic target in CTDs.

【 授权许可】

Unknown